ArticleThe Journal of infectious diseases2016
Vaccine-Induced Immunogenicity and Protection Against Pneumocystis Pneumonia in a Nonhuman Primate Model of HIV and Pneumocystis Coinfection.
Article in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 33 citations in OpenAlex.
- Development of a vaccine construct againstNAR genomics and bioinformatics · 2025Article
- Active and Passive Immunization of Pan-Fungal Vaccine NXT-2 Reduces Morbidity and Mortality in an Immunosuppressed Murine Model ofVaccines · 2025Article
- Experimental Pneumocystis infection in dexamethasone immunosuppressed macaques.Medical mycology · 2025Article
- Protective efficacy of the pan-fungal vaccine NXT-2 against vulvovaginal candidiasis in a murine model.NPJ vaccines · 2025Article
- Protective efficacy of a 'pan-fungal' vaccination strategy against experimentalFrontiers in immunology · 2025Article
- Advancements and challenges in antifungal therapeutic development.Clinical microbiology reviews · 2024Review
- More than Just Protein Degradation: The Regulatory Roles and Moonlighting Functions of Extracellular Proteases Produced by Fungi Pathogenic for Humans.Journal of fungi (Basel, Switzerland) · 2023Review
- Immunogenicity and protective efficacy of a pan-fungal vaccine in preclinical models of aspergillosis, candidiasis, and pneumocystosis.PNAS nexus · 2022Article
- Review
- A therapeutic vaccine strategy to preventFrontiers in immunology · 2022Article
- T cell responses to control fungal infection in an immunological memory lens.Frontiers in immunology · 2022Review
- Immune Response inJournal of fungi (Basel, Switzerland) · 2021Review
- Immunization with Pneumocystis carinii A12BMC immunology · 2021Article
- Relationship ofBMJ open respiratory research · 2021Article
- Review
- Vaccine-Induced Protection in Two Murine Models of Invasive Pulmonary Aspergillosis.Frontiers in immunology · 2021Article
- Detection of anti-Pneumocystis jirovecii antibodies in human serum using a recombinant synthetic multi-epitope kexin-based antigen.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Observational
- Reassessing therapeutic antibodies for neglected and tropical diseases.PLoS neglected tropical diseases · 2020Review
- Development of a Gold Nanoparticle-Based Lateral-Flow Immunoassay forFrontiers in microbiology · 2019Article
- Immunization withHuman vaccines & immunotherapeutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe ubiquitous opportunistic pathogen Pneumocystis jirovecii causes pneumonia in immunocompromised individuals, including human immunodeficiency virus (HIV)-infected individuals, and pulmonary colonization with P. jirovecii is believed to be a cofactor in the development of chronic obstructive pulmonary disease. There is no vaccine for P. jirovecii; however, most adults are seropositive, indicating natural immune priming to this pathogen. We have shown that humoral response to a recombinant subunit of the P. jirovecii protease kexin (KEX1) correlates with protection from P. jirovecii colonization and pneumonia.
methodsHere we evaluated the immunogenicity and protective capacity of the recombinant KEX1 peptide vaccine in a preclinical, nonhuman primate model of HIV-induced immunosuppression and Pneumocystis coinfection.
resultsImmunization with KEX1 induced a robust humoral response remained at protective levels despite chronic simian immunodeficiency virus/HIV-induced immunosuppression. KEX1-immunized macaques were protected from Pneumocystis pneumonia, compared with mock-immunized animals (P= .047), following immunosuppression and subsequent natural, airborne exposure to Pneumocystis
conclusionsThese data support the concept that stimulation of preexisting immunological memory to Pneumocystis with a recombinant KEX1 vaccine prior to immunosuppression induces durable memory responses and protection in the context of chronic, complex immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.